drugset / Trial / NCT02555306
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety, tolerability, immunogenicity, and bioactivity of a single intravitreal (IVT) administration of DE-122 in subjects with refractory exudative age-related macular degeneration (AMD).
Timeline
- Start
- 2015-09-16
- Primary completion
- 2017-08
- Completion
- 2017-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carotuximab | Monoclonal antibody | 0.5 mg | Intravitreal |
| Subject | Carotuximab | Monoclonal antibody | 1 mg | Intravitreal |
| Subject | Carotuximab | Monoclonal antibody | 2 mg | Intravitreal |
| Subject | Carotuximab | Monoclonal antibody | 4 mg | Intravitreal |